The results showed that the serum levels of CEA, CYFRA21-1, SCCA, CA125 and CA199 gradually increased with the patient's disease progression, suggesting that as the NSCLC disease progression increases, the serum tumor marker levels are also increasing (Figure 1A-E). The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.